CanadaBis Capital Announces Expansion into British Columbia New Brands and New Pricing

TSX-V: CANB

Equipped with a refreshed strategy, new products and new provincial markets, the future for Stigma Grow is strong.

CALGARY, AB, Jan. 29, 2021 /CNW/ - CanadaBis Capital Inc. ("CanadaBis" or "the Company") is pleased to announce that its 100% owned subsidiary, 1998643 AB LTD. ("Stigma Grow") is now selling their expanding lineup of first-to-market hydrocarbon cannabis concentrates across British Columbia. 

"We are excited to finally bring our powerful lineup of live-resin concentrates to a province who has long awaited the type of quality, potency and pricing they are used to getting from the legacy market," said Travis McIntyre, CEO of CanadaBis Capital Inc. "For the past few months, we have been revisiting our product categories and pricing models to cater to those consumers who are still looking for more out of LP offerings. We are looking to leverage our relationships and in-house expertise to lead the growth of the concentrates category across Canada – ensuring our brands remain engaging and educational, while our products continue to lead the industry in quality and fair pricing."

Equipped with their cannabis 2.0 direct sales license since December 2020, and with product listings currently across Alberta, BC, Manitoba and Saskatchewan, Stigma Grow is looking to the relaunch of all their products under their own brand name as a chance to introduce new brands, adjust pricing and make the biggest impact possible.

Starting in February of 2021, Stigma Grow will be introducing Dab Bods; a low-cost, high-value hydrocarbon concentrate offering that will bring the lowest price shatter, sugar and more to provinces currently struggling with the high price of existing offerings.

"Dab Bods will be an approachable brand that seeks to introduce concentrates to those who do not have a lot to spend, but who see the value and lifestyle benefits that come from switching over to a more discreet, efficient and effective cannabis product," says Chad Hason, VP of Sales and Marketing for Stigma Grow.

As well, Stigma Grow will be the first-to-market for RSO capsules; a popular and vary potent ingestible popular with high-tolerance consumers and within the medical market. This full-spectrum hydrocarbon capsule comes in various strengths and represents one of the only capsules on the market offering the synergistic benefits of the entourage effect.

Finally, Stigma Grow is reducing the price of their instantly popular, live-resin, HTFSE vape cartridges to compete against the lower costs of a variety of vape cartridge distillates.

"While we work with our valued communities to explain the differences and superior nature of a true live-resin vape offering versus a distillate", explains Chad, "our goal is to present our audiences with the ideal mix of engaging messages, superior product and incredible pricing. Once price or understanding is no longer a barrier to recognizing higher quality, we believe the experiences consumers have will lead to the brand loyalty we seek."

In addition to this the Company has entered into an agreement with an arms-length party who has opted to increase their share hold position within CanadaBis Capital via shares for debt.  

This arrangement, in connection with the Services, the Company has agreed to issue to the (the "Creditor") an aggregate of 558,590 Common Shares in the capital of the Company (the "Debt Shares") at a deemed issue price of $0.10 per Debt Share (the "Debt Settlement").  The issuance of the Debt Shares is subject to the TSX Venture Exchange's final approval.  All Debt Shares issued in connection with the Debt Settlement are subject to a statutory hold period of four months plus a day from the issuance of the Debt Shares in accordance with applicable securities legislation.

About Stigma Grow

Stigma Grow is a cutting-edge cannabis cultivation and extraction company positioned advantageously to meet the unmet market demands and stigmas within the legal cannabis industry head on, with products designed to disturb the status quo and dramatically shift the conversation surrounding Canada's legal cannabis industry.

About CanadaBis Capital Inc.

CanadaBis Capital Inc. (TSXV:CANB) is a vertically integrated Canadian cannabis company focused on achieving large-scale growth in the fast-emerging global cannabis market. By targeting organic growth opportunities alongside the right-fit partners, we remain focused on finding and capitalizing on chances to grow, diversify and continue to lead our industry.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION:
This news release includes certain "forward-looking statements" under applicable Canadian securities legislation. Forward-looking statements include, but are not limited to statements with respect to our business and operations; timing of the Company's profitability; the demand and sales volumes of the Company's products, and our general business plans. Forward-looking statements are necessarily based upon a number of assumptions including: the ability of the Company's products to compete with the pricing and product availability on the black-market; the market demand for the Company's products; and assumptions concerning the Company's competitive advantages. These assumptions, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: compliance with extensive government regulation, the general business, economic, competitive, political and social uncertainties; ability to sustain or create a demand for a product; requirement for further capital; delay or failure to receive board, shareholder or regulatory approvals; the results of operations and such other matters as set out in the Company's continuous disclosure on SEDAR at www.sedar.com. There can be n no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.

Accordingly, readers should not place undue reliance on forward-looking statements. Investors are cautioned that forward-looking information is not based on historical facts but instead reflects management's expectations, estimates or projections concerning future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although we believe that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have a material adverse effect on our future results, performance or achievements.

Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward-looking information except as otherwise required by applicable law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE CanadaBis Capital Inc.

For more information on CanadaBis Capital, 1998643 (Stigma Grow), or INDICAtive Collection please visit www.canadabis.com, www.stigmagrow.ca, www.indicativecollection.ca or contact: Investor Relations [email protected] 1-888-STIGMA1